NCT00191737View on ClinicalTrials.gov

An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

October 31, 2004

Study Completion Date

February 28, 2006

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

Atomoxetine

Trial Locations (2)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cologne

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Freiburg im Breisgau

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00191737 - An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder | Biotech Hunter | Biotech Hunter